

## Technology Advisory Committee A Interests Register

### Tirzepatide for treating type 2 diabetes [ID3938]

Publication Date: 25/10/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Patrick De Barr	TAC A member	Direct - Professional	Patrick previously worked for Sanofi, who could be a possible comparator in the Tirzepatide topic. However, he left in 2020 and has no ongoing financial or non-financial or personal interest with the company.	18/05/2023	N/A	It was agreed that Patrick's declaration would not prevent him from participating in discussions on this appraisal.
Becky Pennington	TAC A member	Financial Interests - Direct	Becky received consultancy fees from Roche and Takeda for research/advice into including carer health-related quality of life in economic evaluation. Neither project was drug or disease-area specific and did not relate to either bevacizumab or alogliptin.	18/05/2023	N/A	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal.
Fiona Macpherson Smith	TAC A member	Non-Financial Professional & Personal Interests	Fiona has a long-standing clinical interest in diabetes in primary care (variously overseeing, planning and operating clinics over the last	02/06/2023 18/07/2023	N/A	It was agreed that Fiona's declaration would not prevent her from participating in

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			decade). She also has an interest in obesity medicine (matters as the med is also used in obesity treatment) – and has an honorary contract with Gloucestershire ICB, linking to clinical and protocol work. She is also studying for a masters in obesity medicine.			discussions on this appraisal.
Michael Cummings, Consultant, Diabetes and Endocrinology at Portsmouth Hospitals University Trust	Clinical expert	Direct – financial	Speaker fees, advisory boards and support for attending congresses by Lilly (intermittent since 1996).	04/07/2022	N/A	It was agreed that Michael's declaration would not prevent him from participating in discussions on this appraisal.
Michael Cummings, Consultant, Diabetes and Endocrinology at Portsmouth	Clinical expert	Direct – non-financial	Honorary Chair, Diabetes and Endocrinology, University of Portsmouth (2008). CLRN Co-Lead, Diabetes Wessex (2008).	04/07/2022	N/A	It was agreed that Michael's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Hospitals University Trust			<p>Participating centre (PI) for SURPASS research programme.</p> <ol style="list-style-type: none"> <li>1. Michael has received honoraria intermittently for advisory boards from Lilly for over 15 years related to Lilly products including Tirzepatide.</li> <li>2. Michael has undertaken research as a principal investigator on Lilly studies intermittently for over 15 years including a study with Tirzepatide.</li> <li>3. Michael has previously received financial support to attend national and international diabetes</li> </ol>			

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			meetings from Lilly or over 20 years.  4. Michael has received honoraria from Lilly over the last 20years for lecturing on diabetes including sponsored meetings that discuss Lilly diabetes products.			
Stephen Bain, Professor of Medicine (Diabetes) at Swansea University Medical School	Clinical expert	Direct – financial	Stephen has received personal financial support (speaker fees and support for attendance at medical conferences) from Lilly (manufacturers of Terzepatide) and the other pharmaceutical company in this therapy space (Novo Nordisk).	23/05/2023	N/A	It was agreed that Stephen's declaration would not prevent him from participating in discussions on this appraisal.
Partha Kar	NHSE expert	Direct – financial	Partha has conducted an educational talk on insulin use for Eli Lilly.	08/10/2023	N/A	It was agreed that Partha's declaration would not prevent him from participating in

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
						discussions on this appraisal.